New Patch Future of HIV Treatment?
The company, with its DermaVir Patch, hopes to use nanomedicines to amplify a human immune response, allowing the body to fight diseases ranging from cancer to HIV. Currently undergoing Phase II clinical trials, the nanomedicine-containing patch holds great promise for HIV patients. As a topically administered HIV immune therapy, the nanomedicine induces the immune system to recognize and kill HIV-infected cells. This new system contains two innovative components, the nanomedicine vaccine and the topical administration. The DermaVir patch delivers the vaccine as nanoparticles, which is taken to the lymph nodes. There, the vaccine induces a strong immune response.
Today's HIV treatments, antiretroviral drugs, can only delay the onset of AIDS symptoms. The drugs produce uncomfortable side effects, and patients can develop resistance. Treatment must be received at least once daily.
In contrast, the DermaVir Patch promises to amplify the immune system, helping the body's own defenses attack and kill HIV-infected cells, and develop an immune response toward the devastating virus. In trials, patients have not experienced resistance. So far, the DermaVir Patch has not caused toxic reactions in any patient. It can be used with existing therapies. Furthermore, with the DermaVir Patch, patients should not need to receive treatments more than nine times per year.
Power of the Dream Ventures, a Hungarian-based technology company, has recently partnered with Genetic Immunity to assist their efforts.
"We are extremely happy to be working with Genetic Immunity. They are on the cusp of introducing a number of significant medical products," said Power of the Dream Ventures CEO Viktor Rozsnyay. "It is our privilege to help them communicate to the world all that they have achieved over the past years, and to bring both investor and public awareness to their important work."
For more information, visit www.geneticimmunity.com and www.powerofthedream.com.
No comments: